A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 19 Jan 2016 Planned End Date changed from 1 Feb 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
- 30 Sep 2014 Status changed from active, no longer recruiting to completed, as reported at the 39th European Society for Medical Oncology Congress.